Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's What Happened

Key Points

• Trading volume jumped 35% to 967,495 shares with the stock last at $27.92 and trading up roughly 4.5% from the prior close.
• Analysts are broadly bullish, giving a MarketBeat consensus "Buy" rating with an average price target of $66 and several firms raising targets (HC Wainwright to $110, JPMorgan to $58).
• Insiders have sold 95,000 shares valued at about $4.25M in the past 90 days, while institutions like Janus Henderson increased their stake 318%, signaling mixed insider/institutional activity.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares saw an uptick in trading volume on Tuesday . 967,495 shares changed hands during trading, an increase of 35% from the previous session's volume of 717,528 shares.The stock last traded at $27.92 and had previously closed at $27.42.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MAZE. Mizuho upgraded shares of Maze Therapeutics to a "strong-buy" rating in a report on Wednesday, March 11th. BTIG Research reiterated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, March 25th. HC Wainwright lifted their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, March 25th. JPMorgan Chase & Co. lifted their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an "overweight" rating in a report on Tuesday, March 31st. Finally, Guggenheim lifted their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $66.00.

Maze Therapeutics Trading Up 4.5%

The company's 50-day simple moving average is $42.11 and its 200 day simple moving average is $38.25. The stock has a market cap of $1.42 billion, a P/E ratio of -8.79 and a beta of 5.16.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Insiders Place Their Bets

In other Maze Therapeutics news, SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $46.04, for a total transaction of $230,200.00. Following the transaction, the senior vice president owned 12,965 shares of the company's stock, valued at $596,908.60. This trade represents a 27.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Harold Bernstein sold 30,000 shares of Maze Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 95,000 shares of company stock valued at $4,245,625 in the last 90 days.

Institutional Trading of Maze Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its position in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company's stock worth $130,197,000 after acquiring an additional 2,390,713 shares during the period. Vanguard Group Inc. raised its position in Maze Therapeutics by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company's stock worth $70,307,000 after acquiring an additional 362,060 shares during the period. Woodline Partners LP raised its position in Maze Therapeutics by 10.0% in the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company's stock worth $26,843,000 after acquiring an additional 94,529 shares during the period. Marshall Wace LLP raised its position in Maze Therapeutics by 9.0% in the fourth quarter. Marshall Wace LLP now owns 847,472 shares of the company's stock worth $35,111,000 after acquiring an additional 69,771 shares during the period. Finally, ArrowMark Colorado Holdings LLC raised its position in Maze Therapeutics by 40.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company's stock worth $31,793,000 after acquiring an additional 222,251 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.